Objective:Comparative analysis of GABA Fusobacterium triple viable colloidal bismuth tartrate tablets were joint capsule triple therapy for the treatment of Helicobacter pylori infection in elderly peptic ulcer clinical results. Method:The 150 cases of infection caused by Helicobacter pylori peptic ulcer in elderly patients were randomly divided into GABA Fusobacterium triple viable tablet group (referred to as the viable group), colloidal bismuth tartrate capsules group (capsule group) and pure triple groups all 50 cases, viable cells were given GABA Fusobacterium triple viable tablet combined triple therapy treatment group were given capsules colloidal bismuth tartrate capsules combined with triple therapy, a simple triple group received standard triple therapy. 4 weeks after treatment clinical efficacy of three groups of patients, H. pylori clearance and adverse reactions. Results:After treatment, the viable group, the total effective rate 94.00%, 90.00% Helicobacter pylori eradication rate were significantly higher than capsules group (P<0.05); the worst effect of pure triple group (P<0.05);there are some capsule group nephrotoxicity. Conclusion:GABA Fusobacterium triple viable tablet combined with triple therapy is superior to bismuth tartrate capsules combined with triple therapy and simple triple therapy, and colloidal bismuth tartrate capsules combined with triple therapy has some kidney toxicity, does not apply to elderly patients, requires a combination of the patient''s condition and take exercise Select the certificate of medical treatment after differentiation.%目的:比较分析酪酸梭菌肠球菌三联活菌片与胶体酒石酸铋胶囊分别联合三联疗法对治疗幽门螺杆菌感染所致消化性溃疡临床效果. 方法:将150例幽门螺杆菌感检测阳性的老年消化性溃疡患者随机分为酪酸梭菌肠球菌三联活菌片组(简称活菌组)、胶体酒石酸铋胶囊组(简称胶囊组)和单纯三联组,每组50例,活菌组给予酪酸梭菌肠球菌三联活菌片联合三联疗法治疗,胶囊组给予胶体酒石酸铋胶囊联合三联疗法治疗,单纯三联组只给予标准三联治疗. 治疗5周后比较三组临床疗效、幽门螺杆菌清除率及不良反应. 结果:治疗后,活菌组总有效率为94.00%,幽门螺杆菌清除率为90.00%,均显著高于胶囊组(P<0.05);单纯三联组疗效最差(P<0.05);胶囊组存在一定的肾脏毒性. 结论:酪酸梭菌肠球菌三联活菌片联合三联疗法要优于胶体酒石酸铋胶囊联合三联疗法和单纯三联疗法,胶体酒石酸铋胶囊联合三联疗法存在一定肾毒性,对老年患者不适用,需要结合患者情况并采取询证医学辨证后选择治疗方式.
展开▼
